Literature DB >> 25902322

The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.

Louis-Philippe Fortier1, Dolores McKeen, Kim Turner, Étienne de Médicis, Brian Warriner, Philip M Jones, Alan Chaput, Jean-François Pouliot, André Galarneau.   

Abstract

BACKGROUND: Postoperative residual neuromuscular blockade (NMB), defined as a train-of-four (TOF) ratio of <0.9, is an established risk factor for critical postoperative respiratory events and increased morbidity. At present, little is known about the occurrence of residual NMB in Canada. The RECITE (Residual Curarization and its Incidence at Tracheal Extubation) study was a prospective observational study at 8 hospitals in Canada investigating the incidence and severity of residual NMB.
METHODS: Adult patients undergoing open or laparoscopic abdominal surgery expected to last <4 hours, ASA physical status I-III, and scheduled for general anesthesia with at least 1 dose of a nondepolarizing neuromuscular blocking agent for endotracheal intubation or maintenance of neuromuscular relaxation were enrolled in the study. Neuromuscular function was assessed using acceleromyography with the TOF-Watch SX. All reported TOF ratios were normalized to the baseline values. The attending anesthesiologist and all other observers were blinded to the TOF ratio (T4/T1) results. The primary and secondary objectives were to determine the incidence and severity of residual NMB (TOF ratio <0.9) just before tracheal extubation and at arrival at the postanesthesia care unit (PACU).
RESULTS: Three hundred and two participants were enrolled. Data were available for 241 patients at tracheal extubation and for 207 patients at PACU arrival. Rocuronium was the NMB agent used in 99% of cases. Neostigmine was used for reversal of NMB in 73.9% and 72.0% of patients with TE and PACU data, respectively. The incidence of residual NMB was 63.5% (95% confidence interval, 57.4%-69.6%) at tracheal extubation and 56.5% (95% confidence interval, 49.8%-63.3%) at arrival at the PACU. In an exploratory analysis, no statistically significant differences were observed in the incidence of residual NMB according to gender, age, body mass index, ASA physical status, type of surgery, or comorbidities (all P > 0.13).
CONCLUSIONS: Residual paralysis is common at tracheal extubation and PACU arrival, despite qualitative neuromuscular monitoring and the use of neostigmine. More effective detection and management of NMB is needed to reduce the risks associated with residual NMB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25902322     DOI: 10.1213/ANE.0000000000000757

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  35 in total

1.  Delayed Recovery from Anaesthesia: Missing Information.

Authors:  Karthikeyan Kallidaikurichi Srinivasan
Journal:  J Clin Diagn Res       Date:  2016-10-01

2.  Sugammadex: An Update.

Authors:  Tiberiu Ezri; Mona Boaz; Alexander Sherman; Marwan Armaly; Yitzhak Berlovitz
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-02-09

Review 3.  Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations.

Authors:  A Thorell; A D MacCormick; S Awad; N Reynolds; D Roulin; N Demartines; M Vignaud; A Alvarez; P M Singh; D N Lobo
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

4.  Neuromuscular Block and Blocking Agents in 2018.

Authors:  Christoph Unterbuchner
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-04-01

Review 5.  Neuromuscular monitoring: an update.

Authors:  Mădălina Duţu; Robert Ivaşcu; Oana Tudorache; Darius Morlova; Alina Stanca; Silvius Negoiţă; Dan Corneci
Journal:  Rom J Anaesth Intensive Care       Date:  2018-04

6.  Optimizing Reversal of Neuromuscular Block in Older Adults: Sugammadex or Neostigmine.

Authors:  Brandon M Togioka; Katie J Schenning
Journal:  Drugs Aging       Date:  2022-08-08       Impact factor: 4.271

7.  Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis.

Authors:  Sachin Kheterpal; Michelle T Vaughn; Timur Z Dubovoy; Nirav J Shah; Lori D Bash; Douglas A Colquhoun; Amy M Shanks; Michael R Mathis; Roy G Soto; Amit Bardia; Karsten Bartels; Patrick J McCormick; Robert B Schonberger; Leif Saager
Journal:  Anesthesiology       Date:  2020-06       Impact factor: 7.892

Review 8.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

9.  International survey of neuromuscular monitoring in two European countries: a questionnaire study among Hungarian and Romanian anaesthesiologists.

Authors:  Adrienn Pongrácz; Réka Nemes; Caius Breazu; László Asztalos; Ileana Mitre; Edömér Tassonyi; Béla Fülesdi; Calin Mitre
Journal:  Rom J Anaesth Intensive Care       Date:  2019-04

10.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.